Indications
Kerendia is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. For study results with respect to renal and cardiovascular events, see section 5.1. Kerendia is indicated for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≥ 40% in adults.
Composition
- Active substance
- finerenone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kerendia
- Active substance
- finerenone
- ATC code
- C09
- Therapeutic area
- Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2, Heart Failure
- Marketing authorisation holder